title: New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy.
abstract: The best initial therapy for steroid-sensitive nephrotic syndrome (SSNS) in children is subject to ongoing debate. Systematic reviews and meta-analyses have concluded that at least 3 months and up to 7 months of treatment would reduce the number of relapses by 30%. But summarizing small underpowered studies cannot eliminate the basic flaws in design. Two well-powered randomized prospective trials now come to the opposite conclusion, and these results should impact the management of children with SSNS.
authors.affiliation: Zentrum für Kinder- und Jugendmedizin, Klinik für Kinderheilkunde II, Universität Duisburg-Essen, Essen, Germany.
authors.forename: Peter F
authors.initials: PF
authors.lastname: Hoyer
mesh_terms: D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage*
chemical_list: D005938:Glucocorticoids; D011239:Prednisolone